I understand and agree with the above statement

Country

Title

Family Name

Middle Names

First Name

Please indicate the organization under whose behalf you are responding to this survey

Actual position title

Official Email

Gender

2.1 Which approach characterizes the current surveillance and containment of AMR threat in the country?

2.2 Please select the surveillance sectors covered in the adopted (or, developed) NAP

2.3 Does the country have an antimicrobial resistance coordination committee (AMRCC)?

2.4 Does the country have a One Health secretariat?

3.1 Choose the number that best characterizes the implementation status of the national action plan on antimicrobial resistance?

3.2 Which year has the NAP implementation started?

3.3 What has been the main source of financial support for the development of AMR NAP?

3.4 What has been the main source of financial support for the implementation of AMR NAP?

3.5 What has been the main source of financial support for the review and update of AMR NAP?

4.1 How are AMR containment policies developed in the country? Select all that apply

4.2 How high of a priority is the containment of antimicrobial resistance on the national (general) political agenda?

4.3 How high of a priority is the containment of antimicrobial resistance on the national health policy agenda?

4.4 What are the top 4 policies for AMR containment currently prioritized by the country? (Select max 4)

4.5 Please provide references of those top priority policies or describe the reason(s) why you cannot provide reference

4.6 How frequently are these policies reviewed and updated?

4.7 Please indicate separately the authority and affiliated members responsible for AMR containment policies’ proposal (drafting)/ review/ adoption/ update ?

4.8 Are national public consultations on AMR containment policies regularly held? (the issue can be part of a broader consultation topic)

4.9 Are there any laws or regulations requiring antibiotics to be dispensed on prescription?

4.10 Is there a National Essential Medicines List?

4.11 Are there any applicable laws or regulations regarding the prescription and sale of antimicrobials for animals?

4.12 Are there any applicable laws or regulations regarding the use of antimicrobials as growth promotors?

4.13 Is there a nationwide applicable Infection Prevention and Control strategy?

5.1 Have the costs of implementing the AMR NAP been calculated?

5.2 What approximate proportion of this amount is currently available for the country (if possible, detail separately the proportion of domestic and external funds available.

Please write funds separated as Overall funds available(%), Domestic funds available(%), External funds available(%)

5.3 If applicable, how would you explain the gaps in resource availability that hinder AMR surveillance and control efforts?

5.4 Specify any immediate action that could contribute to bridging these gaps

6.1 Rank the following types of surveillance according to their degree of operationality at national level (The first number being the most operational – the last number being the least operational)

1. Antimicrobial resistance surveillance in humans 2. Antimicrobials use and consumption surveillance in humans 3. Antimicrobial resistance surveillance in animals 4. Antimicrobials use and consumption surveillance in animals 5. Antimicrobial resistance surveillance in environment 6. Genomic surveillance

6.2 What are the key sources of data for national AMR surveillance?

6.3 Beyond GLASS, are there nationwide standardized protocols to collect and report on data related to AMR in human health ?

6.4 Which specimen data are routinely collected for surveillance of AMR in human health?

6.5 How are clinical patient data mostly recorded in hospitals and tertiary care sector across the country?

Patient data eg., reason for admission, diagnosis, medical history, treatments, dates of admission to and discharge from hospital, symptoms, reason for death, etc.

6.6 In most instances, are medical records only accessible within a specific healthcare facility, shared between a network of hospitals/clinics, or accessible on a centralized national platform? (add details/specify)

6.7 Where can death registries be found?

6.8 Are data related to AMR captured in death registries (eg. reason for death: infection due to a resistant microorganism) ?

6.9 Beyond GLASS, are there nationwide standardized protocols to collect and report on data related to humans AMC/AMU data?

6.10 Who is in charge (officially or unofficially) of collecting AMC/AMU data? Select all that apply

6.11 What are the main obstacles to implementing national AMC/AMU surveillance related to human health?

6.12 Are there nationwide standardized protocols to collect and report data related to AMR in animal health ?

6.13 Are there nationwide standardized protocols to collect and report data related to AMC/AMU in animals ?

6.14 Do you have any Monitoring and Evaluation (M&E) framework for your surveillance network?

6.15 Is the described system performance M&E sufficiently sustainable?

7.1 How are human health, animal health, and environmental health sectors collaborating to address AMR?

7.2 If applicable to the country approach, what are the challenges in implementing a One Health approach to AMR surveillance and control?

7.3 What level of efforts is needed to implement and develop a OneHealth integrated surveillance system?

8.1 How would you quantify the level of engagement of civil society on the issue of AMR?

8.2 Are there any national patient association for victims of AMR burden?

9.1 Which regional and global partners are mostly supporting the containment of AMR burden in your country?

9.2 What role do these partners play in supporting AMR surveillance and control efforts

9.3 Are there any challenges in collaborating with these partners?

9.4 How well are AMR/AMC/AMU surveillance actors in human health identified and engaged at national level?

9.5 How well are AMR/AMC/AMU surveillance actors in animal health identified and engaged at national level?

9.6 How well are actors responsible for AMR surveillance in the environment identified and engaged at national level?

9.7 What immediate solution would help to improve the identification and engagement of those partners?

10.1 Has any analysis aiming at estimating the burden of AMR on human health been conducted in the country in the past 5 years?

10.2 Has any analysis aiming at estimating the socioeconomic burden of AMR been conducted in the country in the past 5 years?

10.3 Were the findings of those burden analyses utilized to inform decision-making process related to AMR containment?

Please feel free to provide any additional comments or insights related to AMR surveillance, data collection, national action plans, One Health initiatives, policies, burden analysis, partnerships, and resource availability.